Oncotarget is Again on MEDLINE

BUFFALO, NY- October 27, 2022 – On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by MEDLINE/PubMed and PubMed Central/PubMed.

Listen to an audio version of this press release

The United States government is firmly committed to making credible biomedical research available to the public. In operation since 1996, PubMed is an online biomedical literature database operated by the U.S. National Institutes of Health (NIH). PubMed provides free access to over 34 million citations from MEDLINE, PubMed Central (PMC) and the National Center for Biotechnology Information databases. 

Started back in the 1960s, MEDLINE is a large bibliographic citation and abstract database for life science articles in journals and other scientific publications. MEDLINE now contains more than 29 million references to articles in over 5,200 journals. In 2000, PMC was launched as a free, full-text archive of biomedical and life sciences journal literature. 

Both MEDLINE and PMC are operated by the NIH’s National Library of Medicine. Importantly, PubMed and MEDLINE use the same controlled vocabulary thesaurus, called Medical Subject Headings, or MeSH, to ensure that content is easily searchable and properly indexed. The vast scope of scholarly publications in MEDLINE is why Oncotarget is proud to have its papers indexed by this database.

Oncotarget, launched in 2010, is a peer-reviewed, open-access and primarily oncology-focused biomedical journal. This journal has international reach—publishing research from world-renowned institutions. The cornerstones of Oncotarget’s publishing practices are insightful peer review, scientific integrity, rigorous ethical standards, up-to-date tools and resources, and a commitment to local and scientific communities. Oncotarget aims to maximize research impact, eliminate borders between specialties and foster the application of basic and clinical science.


To learn more about Oncotarget, visit and connect with us on social media:

For media inquiries, please contact

Leave a Reply

Your email address will not be published. Required fields are marked *